Overview

• On August 5, eMed Population Health confirmed Linda Yaccarino as its new CEO, following her departure from X last month
• Yaccarino will apply her expertise in brand partnerships and digital-revenue growth to scale eMed’s on-demand management platform for obesity and diabetes drugs
• Founded in Miami in 2020, eMed shifted from at-home COVID-19 testing to overseeing GLP-1 therapies and says it can reduce program costs by up to 50%
• The company has secured $22 million in funding to date and works with employers and government payers to broaden patient access to GLP-1 treatments
• Industry analysts predict up to 15 million U.S. adults could be on GLP-1 medications by 2030, creating a market forecast to reach $100 billion annually